All products that were registered by Sandoz Korea will be removed from Korea’s reimbursement list. The company had withdrawn from the Korean market in June.

With the removal, the name Sandoz will no longer be visible in the Korean market. However, a grace period of 6 months has been granted for some items, and reimbursement for such drugs is valid until February 1 next year.

Its CNS (central nervous system) items that have solidified their position in the domestic market will be transferred to Samil Pharmaceutical, and be changed accordingly in the reimbursement list.

According to industry sources on the 25th, 18 products from Sandoz Korea will be removed from the reimbur